Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/23/2022 | $10.00 | Outperform | Baird |
HC Wainwright & Co. analyst Edward White downgrades TRACON Pharma (OTC:TCON) from Buy to Neutral.
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 77.4% to $6.19 during Monday's pre-market session. The company's market cap stands at $3.5 million. ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 35.9% to $0.14. The company's market cap stands at $2.4 million. Venus Concept (NASDAQ:VERO) stock increased by 22.86% to $1.15. The company's market cap stands at $7.3 million. Tharimmune (NASDAQ:THAR) shares moved upwards by 19.4% to $4.0. The company's market cap stands at $3.1 million. TRACON Pharma (NASDAQ:TCON) stock moved upwards by 19.04% to $1.5. The market value of their outstanding shares is at $4.0 million. Kineta (NASDAQ:KA) shares moved upwards by
Shares of Broadcom Inc. (NASDAQ:AVGO) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for its second quarter. The company declared a quarterly dividend of $5.25 per share and also announced a 10-for-1 forward stock split. Broadcom boosted its fiscal year 2024 revenue guidance to approximately $51 billion, up from approximately $50 billion. Broadcom shares surged 13.5% to $1,698.20 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Neo-Concept International Group Holdings Limited (NASDAQ:NCI) rose 79.3% to $1.17 in pre-market trading. Fangdd Network Group Ltd. (NASDAQ:DUO) sh
15-12G - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)
EFFECT - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)
EFFECT - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)
3 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)
4 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)
4 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in
The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11% Company will focus on exploring strategic alternatives, that may include a variety of strategic transactions such as a reverse merger, acquisition, sale of all assets, or other strategic transactions leveraging its in-house Product Development Platform of CRO-independent clinical trial execution SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON) today announced the objective response rate (ORR) by blinded independent central review (BICR) in the fully
Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy Consistent with the TRC102 Mechanism of Action, Extended Survival was Demonstrated in Patients with Activation of DNA Damage Response Pathways Prior to TRC102 Treatment SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science c
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in
SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Carol Lam to its Board of Directors. "We are very pleased to welcome Carol to our Board of Directors," said Dr. Charles Theuer, President and Chief Executive Officer of TRACON. "She brings a global perspective on technology development acquired through her extensive experience as deputy General Counsel
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and the granting of an inducement equity award to Dr. Marczi. "We are very pleased to welcome Brenda to the senior management team at TRACON," said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. "
SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)
SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)
SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)
Baird initiated coverage of TRACON Pharmaceuticals with a rating of Outperform and set a new price target of $10.00
Alliance Global Partners initiated coverage of TRACON Pharmaceuticals with a rating of Buy and set a new price target of $13.00
BTIG Research upgraded Tracon Pharmaceuticals from Neutral to Buy and set a new price target of $14.00
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. "With ENVASARC fully enrolled we are focused on leveraging our Product Development Platform to generate non-dilutive capital through either an additional license or by replacing a CRO and executi
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results. Date:May 14, 2024Time:4:30 pm Eastern Time (1:30 pm Pacific Time)Conference Call:In order t
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. "We are on track to complete enrollment of 80 patients treated with single agent envafolimab in the ongoing pivotal ENVASARC trial later this quarter. We expect to report updated